Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07564934 · ClinicalTrials.gov registry record · Phase 2

Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilities

A Phase 2 study, sponsored by University of Alabama at Birmingham.

Not yet
Registry status
Phase 2
Development phase
130
Enrollment target

NCT07564934: Clinical Trial Phase 2 study, sponsored by University of Alabama at Birmingham.

NCT07564934 is a Phase 2 study that has not yet begun recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 130 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07564934, a Phase 2 study, has not yet begun recruiting, sponsored by University of Alabama at Birmingham.

NOT YET RECRUITING
Registry status
Phase 2
Development phase
130 participants
Enrollment target

Study Summary

This phase II RCT evaluates the efficacy of a telehealth-delivered extended reality (XR) exergaming intervention on physical activity, cardiometabolic health, and physical fitness in physically inactive children with cerebral palsy (ages 10 to 17). A total of 130 participants will be randomized to either a 12-week XR exergaming intervention with behavioral coaching or a non-intervention control group, followed by a 24-week sustainability phase. Aim 1 examines immediate and sustained effects on physical activity levels. Aim 2 tests effects on cardiometabolic health indicators including blood lipids, blood pressure, and glycemic markers. Aim 3 explores effects on physical fitness and perceived health. All procedures are conducted remotely via telehealth.

Primary Outcome

The GLTEQ is a 7-day recall survey. The GLTEQ will be scored using a health contribution (HC) score, which equates an HC score of ≥24 to the minimum aerobic guideline of 150 mins/week of moderate exercise.

Interventions

  • BEHAVIORAL Extended Reality Exergaming

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2026-12-01
Est. Completion 2031-05-31
Phase Phase 2
University of Alabama at Birmingham

1,160 total trials

What is known before NCT07564934 opens enrollment

NCT07564934 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.

The record links to 0 conditions, and to 1 intervention - of which Extended Reality Exergaming is the first listed.

NCT07564934 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07564934 about?

NCT07564934 is a clinical study titled "Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilities". This phase II RCT evaluates the efficacy of a telehealth-delivered extended reality (XR) exergaming intervention on physical activity, cardiometabolic health, and physical fitness in physically inactive children with cerebral palsy (ages 10 to 17). A total of 130 participants will be randomized to e...

What is the current status of trial NCT07564934?

This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2026-12-01. Estimated completion is 2031-05-31.

What interventions are being tested in trial NCT07564934?

The interventions under investigation include: Extended Reality Exergaming (BEHAVIORAL).

Who is sponsoring clinical trial NCT07564934?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07564934's enrollment target sits among peer trials

130 543rd of 2000 higher than 1,448 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01492036 · 130 participants

    Long-Term Follow-Up of Recipient of Gene Transfer Research

  • NCT01631617 · 130 participants · Phase 2

    Effects of Treatments on Atopic Dermatitis

  • NCT02368041 · 130 participants

    Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure

  • NCT02604277 · 130 participants · NA

    Suicidal Behavior in Patients Diagnosed With Bipolar Disorder

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07564934, the US trial registry maintained by the National Library of Medicine. NCT07564934 (mid enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.